ACXP · Acurx Pharmaceuticals, Inc.

On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 37,100 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 25,900 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on April 20, 2027.

On February 5, 2025, the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest immediately.

On February 5, 2025, the Reporting Person was granted stock options to purchase 145,500 shares of the Issuer's common stock. These options vest immediately.

On February 5, 2025, the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest immediately.

Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.

Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.

Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.

Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.

Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.

Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

Acquired in a concurrent private placement of warrants by Acurx Pharmaceuticals, Inc. in connection with the registered direct offering of common stock.

Acquired at the offering price in a registered direct offering of common stock by Acurx Pharmaceuticals, Inc.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 17, 2025.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 17, 2025.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 17, 2025.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 17, 2025.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 17, 2025.

On February 23, 2024 (the "Grant Date"), the Reporting Person was granted stock options to purchase 145,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.

On February 23, 2024 (the "Grant Date"), the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.

On February 23, 2024 (the "Grant Date"), the Reporting Person was granted stock options to purchase 250,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.

These transactions involved bona fide gifts by the Reporting Person of an aggregate of 110,000 shares of the Issuer's common stock to certain of the Reporting Person's family members who do not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by such family members, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. These transactions are late due to an inadvertent administrative error and not any error of the Reporting Person.

These transactions involved bona fide gifts by the Reporting Person of an aggregate of 110,000 shares of the Issuer's common stock to certain of the Reporting Person's family members who do not share the Reporting Person's household. The Reporting Person disclaims beneficial ownership of the securities held by such family members, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. These transactions are late due to an inadvertent administrative error and not any error of the Reporting Person.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 15, 2024.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 15, 2024.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 15, 2024.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 15, 2024.

This stock option award is related to service on the Issuer's board of directors granted pursuant to the Issuer's Director Compensation Policy. The shares subject to the options shall vest on June 15, 2024.

On February 13, 2023 (the " Grant Date"), the Reporting Person was granted stock options to purchase 75,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.

On February 13, 2023 (the " Grant Date"), the Reporting Person was granted stock options to purchase 130,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.

On February 13, 2023 (the " Grant Date"), the Reporting Person was granted stock options to purchase 130,000 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date. This transaction is late due to an inadvertent administrative error and not any error of the Reporting Person.